desmopressin melt form 120 μg

PreclinicalSmall molecule

FFurkan Adem Canbaz

desmopressin melt form 120 μg is one of 19 small molecule programs targeting Enuresis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

EnuresisPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Enuresis

#DrugCompanyPhaseTrials

Indocin

LLife Extension Foundation Inc.

Approved

1 2

Pitressin

AAultman Health Foundation

Advil

Myrbetriq

2 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 6

Oxytrol

WWim Janssens

Phase 3

1 7

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

1 8

Strattera

MMap77

Phase 1

1 9

Minirin

Ferring

Phase 3

2 10

Depacon

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enuresis2 trials

A New Check-list Method for Nocturnal Enuresis

Completed·—·Phase 4·NCT03510975·75 enrolled

Uroflowmetry and Nocturnal Enuresis

Active, not recruiting·FFurkan Adem Canbaz··NCT07028645·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for desmopressin melt form 120 μg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — desmopressin melt form 120 μg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for desmopressin melt form 120 μg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Furkan Adem Canbaz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFurkan Adem Canbaz

desmopressin melt form 120 μg

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Enuresis2 trials

References

Drug Info

Quick Facts

Related News